On Friday, Vaxcyte Inc (NASDAQ: PCVX) was 4.04% up from the session before settling in for the closing price of $31.43. A 52-week range for PCVX has been $27.66 – $121.06.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -29.88% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -27.43%. With a float of $125.45 million, this company’s outstanding shares have now reached $129.82 million.
In an organization with 414 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Vaxcyte Inc (PCVX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Vaxcyte Inc stocks. The insider ownership of Vaxcyte Inc is 3.41%, while institutional ownership is 111.78%. The most recent insider transaction that took place on Mar 05 ’25, was worth 353,699. In this transaction SVP, GEN COUNSEL & CORP SEC of this company sold 5,000 shares at a rate of $70.74, taking the stock ownership to the 41,620 shares. Before that another transaction happened on Mar 05 ’25, when Company’s Officer proposed sale 5,000 for $68.87, making the entire transaction worth $344,350.
Vaxcyte Inc (PCVX) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.83 earnings per share (EPS) during the time that was better than consensus figure (set at -0.99) by 0.16. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.43% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.50% during the next five years compared to -29.88% drop over the previous five years of trading.
Vaxcyte Inc (NASDAQ: PCVX) Trading Performance Indicators
You can see what Vaxcyte Inc (PCVX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 11.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.19, a number that is poised to hit -1.24 in the next quarter and is forecasted to reach -5.77 in one year’s time.
Technical Analysis of Vaxcyte Inc (PCVX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.78 million. That was inferior than the volume of 1.79 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 51.91%.
During the past 100 days, Vaxcyte Inc’s (PCVX) raw stochastic average was set at 10.93%, which indicates a significant decrease from 48.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.38 in the past 14 days, which was lower than the 2.09 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.13, while its 200-day Moving Average is $60.77. However, in the short run, Vaxcyte Inc’s stock first resistance to watch stands at $33.17. Second resistance stands at $33.63. The third major resistance level sits at $34.44. If the price goes on to break the first support level at $31.90, it is likely to go to the next support level at $31.09. The third support level lies at $30.63 if the price breaches the second support level.
Vaxcyte Inc (NASDAQ: PCVX) Key Stats
There are 129,823K outstanding shares of the company, which has a market capitalization of 4.25 billion. As of now, sales total 0 K while income totals -463,930 K. Its latest quarter income was 0 K while its last quarter net income were -166,570 K.
